Clinical Research Directory
Browse clinical research sites, groups, and studies.
Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Sponsor: Rennes University Hospital
Summary
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Official title: REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation
Key Details
Gender
All
Age Range
0 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-03-22
Completion Date
2035-04
Last Updated
2026-01-02
Healthy Volunteers
No
Interventions
Sampling bone tissue and blood
Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
Locations (3)
CHU Angers
Angers, France
CHU Brest
Brest, France
CHU Rennes
Rennes, France